Doctors can still get free samples of medicines, but not football tickets or lunch for their spouses, under a revised code of conduct drafted by a global drug industry trade group that counts Eli Lilly as a member.
Eli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
For drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview mirror any more.
Eli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, sources say.
Patent expirations on Gemzar and Zyprexa contributed to the 27-percent earnings decline, but CEO John Lechleiter touted better-than-expected sales of other products.
Amylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly and Co. co-developed the drug, but ended its partnership with Amylin last year.
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
Eli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff of such spending has dropped off 70 percent in the last decade.
Eli Lilly and Co. has won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper marketing of the company's best-selling medication, Zyprexa, raised their costs.
Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.
Fifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES for millions of pregnant women from about 1938 to the early 1970s.
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a wide margin, sending shares down.
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker’s sales.
Eli Lilly and Co. lost patent protection on its $5-billion-a-year best-seller Zyprexa in October, plunging the company into the long-awaited zone of uncertainty that it calls “Years YZ.”
Cancer treatment developer Immunogen Inc. said Tuesday it will receive $20 million from Eli Lilly and Co. and could earn about $200 million in milestone payments under a collaboration agreement with the Indianapolis drugmaker.
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
Takeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over allegations that their Actos diabetes drug causes bladder cancer.
Indianapolis-based Eli Lilly and Co. recently rejected CVS Caremark’s demands for big price discounts on its insulins, leading CVS to kick Lilly’s insulins off its list of recommended drugs.
Indianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S. and European markets.
